Clinical Trial Update: A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. [Phase 3]

View source ↗

Summary

A Phase III trial evaluating the safety and immunogenicity of Hipra's candidate booster for COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• Hipra's candidate booster vaccination

Snippet

Sponsor: Hipra Scientific, S.L.U | Conditions: COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 3 | Status: COMPLETED